Clinical trials play an important role in the development of new and better treatments for psoriasis and psoriatic arthritis. Through clinical trials, companies can learn what treatments are safe and effective for psoriatic diseases, and possibly bring those drugs to the marketplace.
It's important to check with your health care provider to determine if participating in a clinical trial is right for you. Learn more about clinical trials, what questions to ask before participating and the drug approval process.
If you have EVER been diagnosed with psoriasis by a doctor, please take several minutes to complete this confidential web-based survey. Your responses are very important and may help providers better care for patients with psoriasis. Thank you!
If you have previously completed this short survey, please do so one more time as the previous data was not recorded. Click here for more information »
The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16. The safety objective of this study is to evaluate the safety profile of brodalumab in subjects with psoriatic arthritis.
AbbVie is studying the differences in gene expression between normal and psoriasis skin and blood and the effects of potential new drugs on cultures generated from these samples. This study requires a skin biopsy. The participant must be a male or female at least 18 years old and in good health. They must have a clinical diagnosis of psoriasis for at least 6 months. Some prescription medications are allowed but must not be taking prescription blood thinners. The participant must not be allergic to lidocaine or petrolatum or have a history of anaphylaxis. Women must not be pregnant or breast feeding. Up to $1,500 compensation if selected and successful completion of the study.
Are you concerned about inflammation elsewhere in your body? University Hospitals Case Medical Center is conducting a study to determine cardiovascular risk in patients 18-65 years old. Patients must have psoriasis covering > 10% body surface area. We will measure inflammatory blood markers at several time points and perform MRI of your blood vessels at baseline and one year. Your doctor will treat with the oral/biologic treatment of their choice. Patients will be compensated $425 for participating.
A randomized, double-blind, placebo and positive controlled, single and multiple dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CJM112 in chronic plaque-type psoriasis patients.
Condition: Chronic Plaque-type Psoriasis | Phase: Phase 1/Phase 2 | Age Limit: 18 Years
This study aims to see if patient quality of life can be approved after treatment with an injectable medication called ustekinumab for the treatment of generalized psoriasis. The investigators hypothesize that the investigators will see improvement in quality of life.
Condition: Psoriasis | Phase: Phase 4 | Age Limit: 18 Years
The study aims to establish whether defects in immune cell function are shared across multiple autoimmune diseases and whether those problems match to similar genes in the cells.
Condition: Type 1 Diabetes Mellitus | Phase: N/A | Age Limit: 8 Years
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol compared to active comparator and placebo in adults with moderate to severe chronic plaque psoriasis.
Condition: Psoriasis | Phase: Phase 3 | Age Limit: 18 Years
Psoriatic arthritis is a heterogeneous chronic inflammatory disorder involving joints, tendon sheaths, entheses, and the axial skeleton as well as skin and nails. This is an open-label trial with H.P. Acthar Gel (80 units/1mL) Subcutaneous injection administered twice weekly. To evaluate the signs and symptoms of psoriatic arthritis after 12 weeks, including American College of Rheumatology 20,Clinical Disease Activity Index, Disease Activity Index 28, Dactylitis and adverse events.
Condition: Psoriatic Arthritis | Phase: Phase 4 | Age Limit: 18 Years